$PODD
INSULET CORP

2014 Q2 Form 10-Q Financial Statement

#000114519714000025 Filed on May 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $57.58M $55.35M $57.36M
YoY Change -4.19% -3.49% 20.11%
Cost Of Revenue $36.25M $36.35M $32.20M
YoY Change 8.99% 12.89% 17.27%
Gross Profit $31.83M $28.43M $25.16M
YoY Change 18.63% 13.04% 23.94%
Gross Profit Margin 55.28% 51.37% 43.86%
Selling, General & Admin $34.37M $27.92M $26.97M
YoY Change 25.06% 3.52% 4.68%
% of Gross Profit 107.97% 98.17% 107.2%
Research & Development $6.677M $6.779M $4.396M
YoY Change 29.05% 54.21% -19.07%
% of Gross Profit 20.98% 23.84% 17.48%
Depreciation & Amortization $3.030M $3.070M $2.904M
YoY Change 5.94% 5.72% 2.11%
% of Gross Profit 9.52% 10.8% 11.54%
Operating Expenses $41.05M $34.69M $31.36M
YoY Change 25.69% 10.63% 0.55%
Operating Profit -$5.280M -$1.886M -$6.206M
YoY Change -9.31% -69.61% -43.04%
Interest Expense $300.0K $300.0K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$23.78M -$4.193M -$4.328M
YoY Change 419.31% -3.12% 12.74%
Pretax Income -$29.06M -$6.079M -$10.53M
YoY Change 179.39% -42.29% -28.51%
Income Tax $52.00K $65.00K $131.0K
% Of Pretax Income
Net Earnings -$29.11M -$6.144M -$10.67M
YoY Change 176.75% -42.39% -27.84%
Net Earnings / Revenue -50.56% -11.1% -18.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$525.3K -$110.7K -$201.5K
COMMON SHARES
Basic Shares Outstanding 55.41M shares 55.06M shares 53.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $175.5M $145.6M $148.1M
YoY Change 16.3% -1.69% 78.43%
Cash & Equivalents $175.5M $146.4M $148.1M
Short-Term Investments
Other Short-Term Assets $5.700M $7.100M $6.400M
YoY Change -13.64% 10.94% 48.84%
Inventory $8.765M $10.45M $9.199M
Prepaid Expenses
Receivables $41.80M $36.68M $31.11M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $231.8M $199.9M $194.8M
YoY Change 17.6% 2.62% 51.89%
LONG-TERM ASSETS
Property, Plant & Equipment $34.16M $32.56M $24.98M
YoY Change 16.45% 30.32% 25.24%
Goodwill $37.54M $37.54M $37.54M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.919M $1.652M $2.056M
YoY Change 213.84% -19.65% -22.33%
Total Long-Term Assets $93.50M $88.67M $86.14M
YoY Change 5.02% 2.94% -1.51%
TOTAL ASSETS
Total Short-Term Assets $231.8M $199.9M $194.8M
Total Long-Term Assets $93.50M $88.67M $86.14M
Total Assets $325.3M $288.5M $280.9M
YoY Change 13.69% 2.72% 30.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.61M $20.98M $8.544M
YoY Change 62.66% 145.59% -46.95%
Accrued Expenses $24.59M $18.77M $18.02M
YoY Change 21.27% 4.16% 39.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $23.87M $2.800M $14.73M
YoY Change -81.0%
Total Short-Term Liabilities $71.20M $43.12M $42.98M
YoY Change 110.32% 0.32% 31.92%
LONG-TERM LIABILITIES
Long-Term Debt $165.9M $116.3M $106.2M
YoY Change 52.64% 9.5% -4.2%
Other Long-Term Liabilities $1.521M $1.984M $2.186M
YoY Change -32.28% -9.24% 7.16%
Total Long-Term Liabilities $167.4M $118.3M $108.4M
YoY Change 50.92% 9.13% -4.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $71.20M $43.12M $42.98M
Total Long-Term Liabilities $167.4M $118.3M $108.4M
Total Liabilities $242.5M $166.0M $151.4M
YoY Change 64.04% 9.7% 4.05%
SHAREHOLDERS EQUITY
Retained Earnings -$561.8M -$532.7M -$492.2M
YoY Change 11.74% 8.22% 10.74%
Common Stock $55.00K $55.00K $53.00K
YoY Change 1.85% 3.77% 10.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.88M $122.5M $129.5M
YoY Change
Total Liabilities & Shareholders Equity $325.3M $288.5M $280.9M
YoY Change 13.69% 2.72% 30.24%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$29.11M -$6.144M -$10.67M
YoY Change 176.75% -42.39% -27.84%
Depreciation, Depletion And Amortization $3.030M $3.070M $2.904M
YoY Change 5.94% 5.72% 2.11%
Cash From Operating Activities $510.0K -$1.017M -$1.200M
YoY Change -88.33% -15.25% -86.52%
INVESTING ACTIVITIES
Capital Expenditures -$3.590M $2.157M $1.069M
YoY Change 120.25% 101.78% -37.08%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.590M -$2.157M -$1.069M
YoY Change 120.25% 101.78% -37.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.561M $94.36M
YoY Change -96.23% 14806.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.01M -$939.0K $93.04M
YoY Change 25292.31% -101.01% -26912.97%
NET CHANGE
Cash From Operating Activities 510.0K -$1.017M -$1.200M
Cash From Investing Activities -3.590M -$2.157M -$1.069M
Cash From Financing Activities 33.01M -$939.0K $93.04M
Net Change In Cash 29.93M -$4.113M $90.77M
YoY Change 942.86% -104.53% -929.04%
FREE CASH FLOW
Cash From Operating Activities $510.0K -$1.017M -$1.200M
Capital Expenditures -$3.590M $2.157M $1.069M
Free Cash Flow $4.100M -$3.174M -$2.269M
YoY Change -31.67% 39.89% -78.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
20983000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19359000 USD
CY2013Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
40200000 USD
CY2014Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
43862000 USD
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36679000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33067000 USD
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18771000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19478000 USD
CY2014Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P8Y
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
655106000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
651067000 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4400000 USD
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3000000 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7133000 USD
CY2014Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7183000 USD
CY2013Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2760000 USD
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2625000 USD
CY2014Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
146000 USD
CY2013Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
148000 USD
CY2014Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2528000 USD
CY2013Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2908000 USD
CY2014Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1400000 USD
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8234419 shares
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9841775 shares
CY2014Q1 us-gaap Assets
Assets
288528000 USD
CY2013Q4 us-gaap Assets
Assets
287955000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
198198000 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
199857000 USD
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2637000 USD
CY2014Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2752000 USD
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
5390000 USD
CY2014Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
4657000 USD
CY2014Q1 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
9085000 USD
CY2014Q1 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
2409000 USD
CY2014Q1 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
3815000 USD
CY2014Q1 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
1676000 USD
CY2014Q1 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
7409000 USD
CY2014Q1 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
2861000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149727000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145614000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148065000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57293000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
128308000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
123119000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
90772000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4113000 USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54870424 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55261626 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54870424 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55261626 shares
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2014Q1 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.36
CY2013 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.36
CY2014Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36353000 USD
CY2013Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32201000 USD
CY2013Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
103000 USD
CY2014Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
31000 USD
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
620122 shares
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
26523 shares
CY2013Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
143750000 USD
CY2014Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
143750000 USD
CY2013Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
30099000 USD
CY2014Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
27473000 USD
CY2013Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1414000 USD
CY2014Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1268000 USD
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
34000 USD
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
28000 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
900000 USD
CY2014Q1 us-gaap Deferred Revenue
DeferredRevenue
600000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
900000 USD
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
612000 USD
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3070000 USD
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2904000 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
35800000 USD
CY2014Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y5M15D
CY2014Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y2M15D
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.3800
CY2014Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.3300
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0056
CY2014Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0050
CY2014Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15973000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14860000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
4151000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2864000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1806000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2190000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2665000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3251000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18040000 USD
CY2014Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16927000 USD
CY2011 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
32900000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14259000 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13094000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
37536000 USD
CY2014Q1 us-gaap Goodwill
Goodwill
37536000 USD
CY2014Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2013Q1 us-gaap Gross Profit
GrossProfit
25155000 USD
CY2014Q1 us-gaap Gross Profit
GrossProfit
32808000 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10534000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6079000 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4503000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-857000 USD
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3784000 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-288000 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
985000 USD
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-5668000 USD
CY2014Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
41000 USD
CY2013Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
319000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
904000 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1903000 USD
CY2013Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
4355000 USD
CY2014Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
4489000 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
300000 USD
CY2013Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2014Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
4119000 USD
CY2013Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
4457000 USD
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7394000 USD
CY2014Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8979000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
9464000 USD
CY2014Q1 us-gaap Inventory Net
InventoryNet
10449000 USD
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
399000 USD
CY2014Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
443000 USD
CY2014Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1027000 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1671000 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
31000 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
163358000 USD
CY2014Q1 us-gaap Liabilities
Liabilities
166036000 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
288528000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287955000 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
43118000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42374000 USD
CY2014Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
116277000 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
113651000 USD
CY2014Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of the Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the &#8220;OmniPod System&#8221;), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the only commercially-available insulin infusion system of its kind. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (&#8220;PDM&#8221;). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:inherit;font-size:10pt;"> inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#8220;Neighborhood Diabetes&#8221;) in order to expand the Company&#8217;s full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began commercial sale of the OmniPod System in the United States in October 2005. The Company has also expanded the availability of the OmniPod System internationally through its partnerships with Ypsomed Distribution AG (&#8220;Ypsomed&#8221;) and GlaxoSmithKline (&#8220;GSK&#8221;). In August 2011, the Company received CE Mark approval, and in December 2012, the Company received 510(k) clearance for the new OmniPod System from the FDA. The Company began selling its new OmniPod System in 2013. The new OmniPod System is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities.</font></div></div>
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-939000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1069000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93041000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2157000 USD
CY2013Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
1351000 USD
CY2014Q1 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
1595000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1017000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1200000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-6144000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-10665000 USD
CY2014Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
31361000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
34694000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1886000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6206000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
17169000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2012000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2012000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1934000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1974000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
8150000 USD
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1087000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1825000 USD
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1652000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1943000 USD
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1984000 USD
CY2013Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 USD
CY2014Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
265000 USD
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4193000 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4328000 USD
CY2014Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3882000 USD
CY2013Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1320000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2157000 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1069000 USD
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7115000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5940000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94361000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3561000 USD
CY2014Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3100000 USD
CY2013Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2249000 USD
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1992000 USD
CY2013Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3090000 USD
CY2014Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1133000 USD
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1173000 USD
CY2013Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1917000 USD
CY2014Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1967000 USD
CY2014Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
683000 USD
CY2013Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
619000 USD
CY2014Q1 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
693000 USD
CY2013Q1 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
876000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32356000 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32556000 USD
CY2013Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1327000 USD
CY2014Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
891000 USD
CY2013Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0 USD
CY2014Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
618000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6779000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4396000 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-532669000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-526525000 USD
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
57356000 USD
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
69161000 USD
CY2013Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13871000 USD
CY2014Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13656000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4360000 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2995000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
959139 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.12
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7673000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3500 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
163500 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
47929000 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1828613 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1722082 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.59
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.46
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
41625000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1439049 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.46
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
23.27
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
44.61
CY2014Q1 us-gaap Share Price
SharePrice
47.42
CY2013Q4 us-gaap Share Price
SharePrice
37.10
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
31936000 USD
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M15D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M50D
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
266531 shares
CY2013Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
97800000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
124597000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
122492000 USD
CY2014Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55089028 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53052400 shares
CY2013 podd Capital Leasesof Lessee Contingent Rentals Effective Interest Rate
CapitalLeasesofLesseeContingentRentalsEffectiveInterestRate
0.17
CY2014Q1 podd Changein Fair Valueof Call Option Feature
ChangeinFairValueofCallOptionFeature
200000 USD
CY2014Q1 podd Debt Instrument Modified Debt Unamortized Discount
DebtInstrumentModifiedDebtUnamortizedDiscount
52400000 USD
CY2013Q4 podd Debt Instrument Modified Debt Unamortized Discount
DebtInstrumentModifiedDebtUnamortizedDiscount
52400000 USD
CY2013Q1 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1549000 USD
CY2014Q1 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1348000 USD
CY2014Q1 podd Fair Value Assumption Bond Call Strike Price
FairValueAssumptionBondCallStrikePrice
100.00
CY2013Q4 podd Fair Value Assumption Bond Call Strike Price
FairValueAssumptionBondCallStrikePrice
100.00
CY2014Q1 podd Fair Value Assumption Conversion Price
FairValueAssumptionConversionPrice
26.20
CY2013 podd Fair Value Assumption Conversion Price
FairValueAssumptionConversionPrice
26.20
CY2014Q1 podd Fair Value Assumption Coupon Rate
FairValueAssumptionCouponRate
0.0375
CY2013 podd Fair Value Assumption Coupon Rate
FairValueAssumptionCouponRate
0.0375
CY2013 podd Fair Value Assumptions Bond Yield
FairValueAssumptionsBondYield
0.0861
CY2014Q1 podd Fair Value Assumptions Bond Yield
FairValueAssumptionsBondYield
0.0873
CY2014Q1 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
917000 USD
CY2013Q1 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-1826000 USD
CY2014Q1 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2013Q4 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2014Q1 podd Number Of Financial Institution
NumberOfFinancialInstitution
2 location
CY2014Q1 podd Number Of Inches Of Tubing In Conventional Insulin Pump
NumberOfInchesOfTubingInConventionalInsulinPump
42 in
CY2014Q1 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2013Q4 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2014Q1 podd Product Warranty Term
ProductWarrantyTerm
P4Y
CY2013 podd Repayment Periodfor Capital Lease Obligations
RepaymentPeriodforCapitalLeaseObligations
P36M
CY2014Q1 podd Return Period
ReturnPeriod
P45D
CY2014Q1 podd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitures
0.16
CY2014Q1 podd Stock Price Change Percent
StockPriceChangePercent
0.28
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55414556 shares
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
CY2014Q1 dei Trading Symbol
TradingSymbol
PODD

Files In Submission

Name View Source Status
0001145197-14-000025-index-headers.html Edgar Link pending
0001145197-14-000025-index.html Edgar Link pending
0001145197-14-000025.txt Edgar Link pending
0001145197-14-000025-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
podd-20140331.xml Edgar Link completed
podd-20140331.xsd Edgar Link pending
podd-20140331_cal.xml Edgar Link unprocessable
podd-20140331_def.xml Edgar Link unprocessable
podd-20140331_lab.xml Edgar Link unprocessable
podd-20140331_pre.xml Edgar Link unprocessable
podd-2014x03x31_10xq.htm Edgar Link pending
podd-ex311_20140331x10q.htm Edgar Link pending
podd-ex312_20140331x10q.htm Edgar Link pending
podd-ex321_20140331x10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending